FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News

FDA Improperly Influenced Advisors: Verax

Vertax Biomedical says FDA improperly tainted an advisory committee meeting that led to agency approval of a BioMrieux 510(k).

Medical Devices

Custom Device Annual Report Hints

A CDRH Webinar discusses ways to improve required annual reports submitted by manufacturers with a custom device exemption.

Human Drugs

TherapeuticsMD NDA Under Review for Vasomotor Symptoms

FDA accepts for review a TherapeuticsMD NDA for TX-001HR, an investigational bio-identical hormone therapy combination of estradiol and progesterone i...

Human Drugs

IDE Approval Given to InVivo Therapeutics Spine Scaffold

FDA gives IDE approval to InVivo Therapeutics Holdings for a second pivotal clinical study involving the companys Neuro-Spinal Scaffold in patients wi...

Federal Register

Class 2 for Extracorporeal Shock Wave Device

Federal Register notice: FDA classifies the extracorporeal shock wave device for treating chronic wounds into Class 2 (special controls).

Human Drugs

Gottlieb Wants More FDA Staff at International Mail Facilities

FDA commissioner Scott Gottlieb says he wants more agency investigators at international mail facilities to help intercept illegal drug shipments, par...

Federal Register

Comments Sought on Device Reclassification Info Collection

Federal Register notice: FDA seeks comments on an information collection for Reclassification Petitions for Medical Devices 21 CFR Section 860.123 (O...

Human Drugs

Gottlieb Challenges Payors on Drug Prices

In a precedent-breaking speech, FDA commissioner Scott Gottlieb tells health insurers they need to change payment practices to help the biosimilars ma...

Human Drugs

Trial Site Initiation Highly Inefficient: Tufts

A Tufts Center for the Study of Drug Development survey finds that many drug trial sponsors and CROs are somewhat or completely unsatisfied with their...

Human Drugs

Esperion Reports Positive Phase 3 Results for Cholesterol Drug

Esperion reports positive top-line results from a pivotal Phase 3 study (Study 4 or 1002-048) involving its investigational cholesterol-lowering bempe...